{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:06:40Z","timestamp":1792375600222,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jbspin.2018.09.004","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T01:20:09Z","timestamp":1537406409000},"page":"429-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond"],"prefix":"10.1016","volume":"86","author":[{"given":"Renaud","family":"Felten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-857X(21)00942-X","article-title":"The history of lupus erythematosus. From Hippocrates to Osler","volume":"14","author":"Smith","year":"1988","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0025","unstructured":"Bateman T. Practical synopsis of cutaneous diseases. Collins & Croft; 1818."},{"key":"10.1016\/j.jbspin.2018.09.004_bib0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archinte.1954.00240290025003","article-title":"Nitrogen mustard in treatment of systemic lupus erythematosus","volume":"93","author":"Dubois","year":"1954","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/archderm.1956.01550060046009","article-title":"Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report","volume":"73","author":"Lewis","year":"1956","journal-title":"AMA Arch Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780220901","article-title":"Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus?","volume":"22","author":"Albert","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0045","first-page":"126","article-title":"Glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Mosca","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2012.12.001","article-title":"The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science","volume":"12","author":"RKMAC","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0055","doi-asserted-by":"crossref","first-page":"e000157","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent association of glucocorticoids with damage accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of anti-malarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1191\/096120398678919778","article-title":"A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group","volume":"7","author":"Tsakonas","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0070","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1002\/art.34672","article-title":"Predictors of organ damage in systemic lupus erythematosus: the Hopkins lupus cohort","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0080","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.autrev.2011.04.029","article-title":"The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus","volume":"10","author":"Arnaud","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0085","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/ard.2006.067835","article-title":"Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus","volume":"66","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0090","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","article-title":"Influence of smoking on the efficacy of anti-malarials in cutaneous lupus: a meta-analysis of the literature","volume":"72","author":"Chasset","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2015.09.064","article-title":"The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study","volume":"74","author":"Chasset","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2017.08.045","article-title":"Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0105","first-page":"1275","article-title":"Double blind, randomized, controlled clinical trial of methotrexate in systemic lupus erythematosus","volume":"26","author":"Carneiro","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.1780140511","article-title":"Azathioprine in the treatment of systemic lupus erythematosus. A controlled study","volume":"14","author":"Sztejnbok","year":"1971","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.1780180106","article-title":"Long-term maintenance therapy with azathioprine in systemic lupus erythematosus","volume":"18","author":"Ginzler","year":"1975","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archinte.1970.00310020099011","article-title":"Treatment of lupus nephritis with azathioprine","volume":"125","author":"Maher","year":"1970","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0130","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10067-015-2987-x","article-title":"Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome","volume":"34","author":"Saavedra","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0135","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/0961203315622821","article-title":"Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study","volume":"25","author":"Fanouriakis","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0140","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1177\/0961203317694259","article-title":"Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre","volume":"26","author":"Rodrigues","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0150","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0155","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0160","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0170","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0175","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0180","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/art.27495","article-title":"Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil","volume":"62","author":"Zahr","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0185","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multicentre open randomized controlled trial comparing ciclosporin vs. azathioprine in patients with severe SLE","volume":"49","author":"Griffiths","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0190","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the cyclofa-lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0200","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0205","first-page":"430","article-title":"Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose","volume":"72","author":"Tanaka","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0210","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/ndt\/gfr484","article-title":"Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis","volume":"27","author":"Li","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0215","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2018.02.049","article-title":"Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter-retrospective study","volume":"79","author":"Cesbron","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0225","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0140-6736(92)90365-A","article-title":"Thalidomide for systemic lupus erythematosus","volume":"339","author":"Bessis","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0230","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s10067-016-3256-3","article-title":"Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China","volume":"35","author":"Wang","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0235","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaad.2016.01.054","article-title":"Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients","volume":"74","author":"Fennira","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0240","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1186\/ar4111","article-title":"Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus","volume":"14","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0245","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaad.2011.01.015","article-title":"Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare","volume":"66","author":"Braunstein","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0250","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0255","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0260","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0265","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0270","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0275","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0280","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0290","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0295","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0300","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0305","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0310","unstructured":"Fischer B, et al. The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sj\u00f6gren's syndrome: a phase IIa double-blind, placebo-controlled randomized trial. ACR Meet Abstr n.d. https:\/\/acrabstracts.org\/abstract\/the-novel-anti-cd40-monoclonal-antibody-cfz533-shows-beneficial-effects-in-patients-with-primary-sjogrens-syndrome-a-phase-iia-double-blind-placebo-controlled-randomized-trial\/ [accessed June 22, 2018]."},{"key":"10.1016\/j.jbspin.2018.09.004_bib0315","unstructured":"Efficacy and safety of ustekinumab, an interleukin 12\/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study. ACR Meet Abstr n.d. http:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-ustekinumab-an-interleukin-1223-inhibitor-in-patients-with-active-systemic-lupus-erythematosus-results-of-a-phase-2-randomized-placebo-controlled-study\/ [accessed March 2, 2018]."},{"key":"10.1016\/j.jbspin.2018.09.004_bib0320","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0990","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0325","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jbspin.2018.09.004_bib0330","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/annrheumdis-2013-204385","article-title":"Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen","volume":"73","author":"Tedeschi","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1830304X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1830304X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:24:38Z","timestamp":1761150278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X1830304X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1297319X1830304X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.09.004","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}